

# CLINICAL PHARMACOLOGY and THERAPEUTICS

## Editor

Walter Modell, M.D.

## Editorial Board

Alvito P. Alvares, Ph.D.  
Wilbert S. Aronow, M.D.  
Arthur J. Atkinson, Jr., M.D.  
Daniel L. Azarnoff, M.D.  
Frank M. Berger, M.D., D.Sc.  
Karl H. Beyer, Jr., M.D., Ph.D.  
Hylan A. Bickerman, M.D.  
Edward A. Carr, Jr., M.D.  
Leighton E. Cluff, M.D.  
Allan H. Conney, Ph.D.  
T. S. Danowski, M.D.  
Arthur C. DeGraff, M.D.  
Peter Dineen, M.D.  
Edward F. Domino, M.D.  
Alvan R. Feinstein, M.D.  
Vladimir Fencel, M.D.  
Max Fink, M.D.  
Robert B. Forney, Ph.D.  
Emil Frei, III, M.D.  
Milo Gibaldi, Ph.D.  
Franz Gross, M.D.  
Arthur Hull Hayes, Jr., M.D.  
Leo E. Hollister, M.D.  
Bartholomew P. Hsi, Ph.D.  
Murray E. Jarvik, M.D.

Ernest Jawetz, M.D., Ph.D.  
Stanley A. Kaplan, Ph.D.  
Attallah Kappas, M.D.  
Arthur S. Keats, M.D.  
Richard H. Kessler, M.D.  
Kenneth G. Kohlstaedt, M.D.  
Louis Lasagna, M.D.  
Louis Lemberger, M.D., Ph.D.  
Gerhard Levy, Pharm.D.  
T. A. Loomis, M.D., Ph.D.  
Daniel S. Lukas, M.D.  
Dean T. Mason, M.D.  
Fletcher H. McDowell, M.D.  
Arno G. Motulsky, M.D.  
Marcus M. Reidenberg, M.D.  
R. K. Richards, M.D.  
L. D. Sabath, M.D.  
David G. Shand, M.B., Ph.D.  
Jay Tepperman, M.D.  
Max Tishler, Ph.D.  
Leroy D. Vandam, M.D.  
Elliot S. Vesell, M.D.  
John G. Wagner, Ph.D.  
E. Leong Way, Ph.D.

**Volume 24, July-December, 1978**  
**The C. V. Mosby Company, St. Louis**

Volume 24  
Copyright © 1978 by  
The C. V. Mosby Company

*All rights reserved*

*Printed in the United States of America*

## Index to volume 24

### Author index

#### A

- ALEXANDER, F. (*See* Dubb et al.), 76  
 ALLEN, M. D. (*See* Greenblatt et al.), 600  
 —. (*See* Shader et al.), 308  
 ANAVEKAR, S. N., SAUNDERS, R. H., WARDELL, W. M., SHOULSON, I., EMMINGS, F. G., COOK, C. E., AND GRINGERI, A. J. Parotid and whole saliva in the prediction of serum total and free phenytoin concentrations, 629  
 —. (*See* Wardell et al.), 133  
 ANDERSEN, J. D. (*See* Waldorff et al.), 162  
 ARONOW, W. S. (*See* Orlando et al.), 531  
 —. (*See* van Herick and Aronow), 678  
 AULD, P. A. M. (*See* Dietrich et al.), 474  
 AVOGARO, A. (*See* Furlanut et al.), 294  
 AZARNOFF, D. L. (*See* Carruthers et al.), 168  
 —. (*See* Huffman et al.), 465

#### B

- BABER, N., HALLIDAY, L., SIBEON, R., LITTLER, T., AND ORME, M. L'E. The interaction between indomethacin and probenecid, 298  
 BACK, D. J., BRECKENRIDGE, A. M., CRAWFORD, F. E., MCIVER, M., ORME, M. L'E., PARK, B. K., ROWE, P. H., AND SMITH, E. Kinetics of norethindrone in women. I. Radioimmunoassay and concentrations during multiple dosing, 439  
 —, —, —, —, —, —. Kinetics of norethindrone in women. II. Single-dose kinetics, 448  
 BAKER, J. (*See* Pandey et al.), 343  
 BAKKE, O. M. (*See* Haram et al.), 590  
 BATEMAN, D. N., KAHN, C., LEGG, N. J., AND REID, J. L. Metoclopramide in Parkinson's disease, 459  
 BEASTALL, G. H. (*See* Lindsay et al.), 650  
 BEATTY, E. S. (*See* Friedman et al.), 16  
 BECKER, K. L. (*See* Wisneski et al.), 219  
 BECKWITH, W. (*See* Zarafonitis et al.), 127  
 BEERMAN, B., GROSCHINSKY-GRIND, M., FÄHR-  
 AEUS, L., AND LINDSTRÖM, B. Placental transfer of furosemide, 560  
 BELL, J. J. (*See* Redmond et al.), 213  
 BENDER, R. A. (*See* Jackson et al.), 101

- BENDING, M. R. (*See* Mucklow et al.), 563  
 BENETELLO, P. (*See* Furlanut et al.), 294  
 BENRAAD, H., DRAYER, J., HOEFNAGELS, W., KLOPPENBORG, P., AND BENRAAD, TH. Role of aldosterone in the antihypertensive effect of spironolactone in essential hypertension, 638  
 BENRAAD, TH. (*See* Benraad et al.), 638  
 BILLINGS, B. J. (*See* MacLeod et al.), 583  
 BLAIR, A. D. (*See* Cutler et al.), 333  
 BOËTHIUS, G., AND SJÖQVIST, F. Doses and dosage intervals of drugs—clinical practice and pharmacokinetic principles, 255 (Commentary)  
 BOLTON, S. M. (*See* Materson et al.), 192  
 BONDIOLI, A. (*See* Sirtori et al.), 683  
 BOXENBAUM, H. (*See* Dixon et al.), 622  
 BRANCH, R. A., SALIH, S. Y., AND HOMEIDA, M. Racial differences in drug metabolizing ability: A study with antipyrine in the Sudan, 283  
 —. (*See* Homeida et al.), 228  
 —. (*See* Rane et al.), 199  
 BRATER, D. C. Effects of probenecid on furosemide response, 548  
 BRECKENRIDGE, A. M. (*See* Back et al.), 439, 448  
 BREIMER, D. D., ZILLY, W., AND RICHTER, E. Influence of corticosteroid on hexobarbital and tolbutamide disposition, 208  
 BRIGHT, T. P. (*See* Griffiths et al.), 350  
 BROWN, H. S. (*See* Hull et al.), 644  
 BRUCK, E. (*See* Koup et al.), 571  
 BRUNI, J., WILDER, B. J., WILMORE, L. J., PERCHALSKI, R. J., AND VILLARREAL, H. J. Steady-state kinetics of valproic acid in epileptic patients, 324  
 BURKI, N. K., AND DIAMOND, L. Long-term oral bronchodilator therapy of asthma with pirbuterol, 84  
 BURTON, Z. C. (*See* Materson et al.), 192  
 BUTZ, R. F. (*See* Findlay et al.), 60

#### C

- CARLINER, N. H. (*See* Narang et al.), 654  
 CARRUTHERS, S. G., HOSLER, J. P., PENTIKAINEN, P., AND AZARNOFF, D. L. Pamatolol: Phase I evaluation of the pharmacodynamics of a cardioselective beta adrenoceptor blocking drug, 168

- CASTLE, M. C. (See Jackson et al.), 101  
 CERIMELE, B. J. (See Griffis et al.), 350  
 CHANG, R. L. (See Klutch et al.), 287  
 CHANG, S. (See Pandey et al.), 343  
 CHAPLIN, M. (See Runkel et al.), 706  
 CHI, S. L. (See Hull et al.), 644  
 CIGHETTI, G. (See Sirtori et al.), 683  
 CLARK, J. H. (See Jusko et al.), 406  
 CLEMENTS, J. A., HEADING, R. C., NIMMO, W. S.,  
 AND PRESCOTT, L. F. Kinetics of acetaminophen absorption and gastric emptying in man, 420  
 COHEN, I. M., AND KATZ, M. A. Oral clonidine loading for rapid control of hypertension, 11  
 COLBURN, W. A. (See Koup et al.), 571  
 COLE, O., POPE, H. G., JR., LABRIE, R., AND IONESCU-POGGIA, M. Assessing the subjective effects of stimulants in casual users, 243  
 COLE, P. V. (See Sutton et al.), 395  
 CONNEY, A. H. (See Klutch et al.), 287  
 CONRADI, E. C. (See Walle et al.), 668  
 CONTI, F. (See Sirtori et al.), 683  
 COOK, C. E. (See Anavekar et al.), 629  
 —. (See Drayer et al.), 31  
 CRAWFORD, F. E. (See Back et al.), 439, 448  
 CROOM, W. P. (See Wisneski et al.), 219  
 CROUTHAMEL, W. G. (See Narang et al.), 654  
 CUTLER, R. E., BLAIR, A. D., AND KELLY, M. R. Flucytosine kinetics in subjects with normal and impaired renal function, 333  
 —. (See Lai et al.), 316

## D

- DAINESE, R. (See Furlan et al.), 294  
 DANAHEY, D. T. (See Orlando et al.), 531  
 DAVIES, D. L. (See Lindsay et al.), 650  
 DAVIS, J. M. (See Pandey et al.), 343  
 DAVIS, J. W. (See Yue and Davis), 240  
 DESMOND, P. V. (See Kraus et al.), 411  
 DEWITT, F. O. (See Schneck et al.), 714  
 DIAMOND, L. (See Burki and Diamond), 84  
 DIETRICH, J., KRAUSS, A. N., REIDENBERG, M., DRAYER, D. E., AND AULD, P. A. M. Alterations in state in apneic pre-term infants receiving theophylline, 474  
 DIGREGORIO, G. J., PIRAINO, A. J., AND RUCH, E. Diazepam concentrations in parotid saliva, mixed saliva, and plasma, 720  
 DIXON, R., YOUNG, R., MOHACSI, E., HOLAZO, A., MALAREK, D., BOXENBAUM, H., MOORE, J., PARSONNET, M., AND KAPLAN, S. (-)-2-Hydroxy-N-cyclopropylmethylmorphinan: Radioimmunoassay and pharmacokinetic profile, 622  
 DOBBS, R. J. (See Richards et al.), 264  
 DOLLERY, C. T. (See Mucklow et al.), 563  
 DRAYER, D. E., LOWENTHAL, D. T., RESTIVO, K. M., SCHWARTZ, A., COOK, C. E., AND REIDENBERG, M. M. Steady-state serum levels of quinidine and active metabolites in cardiac patients with varying degrees of renal function, 31  
 —. (See Dietrich et al.), 474  
 DRAYER, J. (See Benraad et al.), 638  
 DUBB, J. W., STOTE, R. M., FAMILIAR, R. G., LEE, K., AND ALEXANDER, F. Effect of cimetidine on renal function in normal man, 76  
 DURAIRAJ, S. K., AND HAYWOOD, L. J. Hemodynamic effects of dopamine in patients with resistant congestive heart failure, 175  
 DUSOUCHE, P. (See McLean et al.), 5 (Commentary)

## E

- EKNOYAN, G. (See Heaney and Eknoyan), 233  
 EMMINGS, F. G. (See Anavekar et al.), 629  
 ENGEL, T. R., DEL C. GONZALEZ, A., MEISTER, S. G., AND FRANKL, W. S. Effect of procainamide on induced ventricular tachycardia, 274  
 ENSMINGER, W. D., AND FREI, E., III. High-dose intravenous and hepatic artery infusions of thymidine, 610

## F

- FAGAN, T. C. (See Walle et al.), 668  
 FÄHRAEUS, L. (See Beermann et al.), 560  
 FAMILIAR, R. G. (See Dubb et al.), 76  
 FARHAT, L. (See Zarafonitis et al.), 127  
 FEINSTEIN, A. R. Clinical biostatistics. XLIV. A survey of the research architecture used for publications in general medical journals, 117  
 —. XLV. The purposes and functions of criteria, 479  
 FEYERABEND, C. (See Sutton et al.), 395  
 FINDLAY, J. W. A., JONES, E. C., BUTZ, R. F., AND WELCH, R. M. Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics, 60  
 FISHER, M. L. (See Narang et al.), 654  
 FORNEY, R. B. (See Griffis et al.), 350  
 FRANCESCHINI, G. (See Sirtori et al.), 688  
 FRANKL, W. S. (See Engel et al.), 274  
 FREI, E., III. (See Ensminger and Frei), 610  
 FRIEDMAN, R. B., YOUNG, D. S., AND BEATTY, E. S. Automated monitoring of drug-test interactions, 16  
 FRIEL, P. (See Wilensky et al.), 22  
 FURLANUT, M., BENETELLO, P., AVOGARO, A., AND DAINESE, R. Effects of folic acid on phenytoin kinetics in healthy subjects, 294

## G

- GAFFNEY, T. E. (See Walle et al.), 668  
 GALLI, G. (See Sirtori et al.), 683  
 GALLI-KIENLE, M. (See Sirtori et al.), 683

- GARDNER, M. (*See* Jusko et al.), 406  
 GEORGOTAS, A. (*See* Shader et al.), 308  
 GIBALDI, M., LEVY, G., AND McNAMARA, P. J. Effect of plasma protein and tissue binding on the biologic half-life of drugs, I (Commentary)  
 —. (*See* Koup et al.), 571  
 —. (*See* McLean et al.), 5 (Commentary)  
 GILES, H. G. (*See* MacLeod et al.), 583  
 GOLBY, R. L., 253 (Correspondence)  
 GOLDBARG, A. (*See* Weisdorf et al.), 663  
 GONZALEZ, A. D. C. (*See* Engel et al.), 274  
 GREENBLATT, D. J., ALLEN, M. D., MACLAUGHLIN, D. S., HARMATZ, J. S., AND SHADER, R. I. Diazepam absorption: Effect of antacids and food, 600  
 —. (*See* MacLeod et al.), 583  
 —. (*See* Shader et al.), 308  
 —. (*See* Stanski et al.), 52  
 GRIFFIS, L. C., BRIGHT, T. P., CERIMELE, B. J., AND FORNEY, R. B. Combined effects of fennetozole and ethanol, 350  
 GRINGERI, A. J. (*See* Anavekar et al.), 629  
 GROSCHINSKY-GRIND, M. (*See* Beermann et al.), 560  
 GROSS, F. The thorny path of clinical pharmacology, 383 (Commentary)  
 GUGLER, R., AND HARTLAPP, J. Clofibrate kinetics after single and multiple doses, 432  
 GWILT, P. R., AND PERRIER, D. Plasma protein binding and distribution characteristics of drugs as indices of their hemodialyzability, 154

## H

- HALLIDAY, L. (*See* Baber et al.), 298  
 HALLIWELL, M. (*See* Homeida et al.), 228  
 HARAM, K., BAKKE, O. M., JOHANNESEN, K. H., AND LUND, T. Transplacental passage of diazepam during labor: Influence of uterine contractions, 590  
 HARAPAT, S. R. (*See* Meffin et al.), 542  
 HARMATZ, J. S. (*See* Greenblatt et al.), 600  
 —. (*See* Shader et al.), 308  
 HARRISON, R. C. (*See* Meffin et al.), 542  
 HARTLAPP, J. (*See* Gugler and Hartlapp), 432  
 HASSAR, M. (*See* Wardell et al.), 133  
 HAYES, A. H., JR. (*See* Schneck et al.), 714  
 HAYWOOD, L. J. (*See* Durairaj and Haywood), 175  
 HEADING, R. C. (*See* Clements et al.), 420  
 HEANEY, D., AND EKNOYAN, G. Minocycline and doxycycline kinetics in chronic renal failure, 233  
 HEEBOLL-NIELSEN, N. (*See* Waldorff et al.), 162  
 HENDERSON, W. G., TOURTELLOTT, W. W., POTVIN, A. R., AND ROSE, A. S. Methodology for analyzing clinical neurological data: ACTH in multiple sclerosis, 146  
 HETTIARRACHCHI, J. (*See* Lindsay et al.), 650  
 HIGNITE, C. E. (*See* Huffman et al.), 465

- HILLIGOSS, D. M. (*See* Koup et al.), 571  
 HOEFNAGELS, W. (*See* Benraad et al.), 638  
 HOLAZO, A. (*See* Dixon et al.), 622  
 HOMEIDA, M., HALLIWELL, M., AND BRANCH, R. A. Effects of an oral contraceptive on hepatic size and antipyrine metabolism in premenopausal women, 228  
 —. (*See* Branch et al.), 283  
 HORLICK, L. (*See* Kudchodkar et al.), 354  
 HOSLER, J. P. (*See* Carruthers et al.), 168  
 HUFFMAN, D. H., KAMPMANN, J. P., HIGNITE, C. E., AND AZARNOFF, D. L. Gynecomastia induced in normal males by spironolactone, 465  
 HULL, J. H., MURRAY, W. J., BROWN, H. S., WILLIAMS, B. O., CHI, S. L., AND KOCH, G. G. Potential anticoagulant drug interactions in ambulatory patients, 644

## I

- INABA, T. (*See* Kalow et al.), 576  
 INWOOD, M. J. (*See* McIntyre et al.), 616  
 IONESCU-POGGIA, M. (*See* Cole et al.), 243

## J

- JACKSON, D. V., JR., CASTLE, M. C., AND BENDER, R. A. Biliary excretion of vincristine, 101  
 JAIN, A. K., McMAHON, F. G., RYAN, J. R., UNGER, D., AND RICHARD, W. Aspirin and aspirin-caffeine in postpartum pain relief, 69  
 JOCHIMSEN, P. R., LAWTON, R. L., VERSTEEG, K., AND NOYES, R., JR. Effect of benzopyranoperidine, a  $\Delta$ -9-THC congener, on pain, 223  
 JOHANNESEN, K. H. (*See* Haram et al.), 590  
 JOHNSON, R. F. (*See* Kraus et al.), 411  
 JONES, E. C. (*See* Findlay et al.), 60  
 JOSSELSO, J., AND SIDELL, F. R. Effect of intravenous thiamine on pralidoxime kinetics, 95  
 JUSKO, W. J., SCHENTAG, J. J., CLARK, J. H., GARDNER, M., AND YURCHAK, A. M. Enhanced biotransformation of theophylline in marihuana and tobacco smokers, 406

## K

- KADAR, D. (*See* Kalow et al.), 576  
 KAHN, C. (*See* Bateman et al.), 459  
 KAHN, G. C. (*See* Mucklow et al.), 563  
 KALOW, W., TANG, B. K., KADAR, D., AND INABA, T. Distinctive patterns of amobarbital metabolites, 576  
 KAMPMANN, J. P. (*See* Huffman et al.), 465  
 KAPLAN, S. (*See* Dixon et al.), 622  
 KATES, R. E., AND LEIER, C. V. Dobutamine pharmacokinetics in severe heart failure, 537  
 KATZ, M. A. (*See* Cohen and Katz), 11  
 KAY, J. L. (*See* Yakatan et al.), 90

- KELLY, M. R. (See Cutler et al.), 333  
 KLAUANS, H. L. (See Weisdorf et al.), 663  
 KLOPPENBORG, P. (See Benraad et al.), 638  
 KLUTCH, A., LEVIN, W., CHANG, R. L., VANE, F., AND CONNEY, A. H. Formation of a thiomethyl metabolite of phenacetin and acetaminophen in dogs and man, 287  
 KOCH, G. G. (See Hull et al.), 644  
 KOUPE, J. R., GIBALDI, M., McNAMARA, P., HILLIGOS, D. M., COLBURN, W. A., AND BRUCK, E. Interaction of chloramphenicol with phenytoin and phenobarbital, 571  
 KRAKAUER, R., AND STEINESS, E. Digoxin concentration in choroid plexus, brain, and myocardium in old age, 454  
 KRAMER, J. (See Weisdorf et al.), 663  
 KRAUS, J. W., DESMOND, P. V., MARSHALL, J. P., JOHNSON, R. F., SCHENKER, S., AND WILKINSON, G. R. Effects of aging and liver disease on disposition of lorazepam, 411  
 KRAUSS, A. N. (See Dietrich et al.), 474  
 KUDCHODKAR, B. J., SODHI, H. S., HORLICK, L., AND MASON, D. T. Mechanisms of hypolipidemic action of nicotinic acid, 354

## L

- LABRIE, R. (See Cole et al.), 243  
 LAI, A. A., LEVY, R. H., AND CUTLER, R. E. Time-course of interaction between carbamazepine and clonazepam in normal man, 316  
 LALKA, D. (See McLean et al.), 5 (Commentary)  
 LASAGNA, L. (See Wardell et al.), 133  
 LASKA, E. (See Sunshine et al.), 555  
 LAWTON, R. L. (See Jochimsen et al.), 223  
 LEE, K. (See Dubb et al.), 76  
 LEFF, R. D. (See Yakatan et al.), 90  
 LEGG, N. J. (See Bateman et al.), 459  
 LEIER, C. V. (See Kates and Leier), 537  
 LEVIN, W. (See Klutch et al.), 287  
 LEVY, G. (See Gibaldi et al.), 1 (Commentary)  
 LEVY, R. H. (See Lai et al.), 316  
 —. (See Wilensky et al.), 22  
 LINDSAY, R., RAMSAY, L. E., HETTIARRACHCHI, J., DAVIES, D. L., AND BEASTALL, G. H. Serum and urine phosphate during short-term  $\beta$ -adrenergic blockade in healthy men, 650  
 LINDSTRÖM, B. (See Beermann et al.), 560  
 LITTLER, T. (See Baber et al.), 298  
 LOWENSTEIN, E. (See Stanski et al.), 52  
 LOWENTHAL, D. T. (See Drayer et al.), 31  
 LUND, T. (See Haram et al.), 590  
 LURIE, M. (See Orlando et al.), 531

## M

- MACLAUGHLIN, D. S. (See Greenblatt et al.), 600

- MACLEOD, S. M., SELLERS, E. M., GILES, H. G., BILLINGS, B. J., MARTIN, P. R., GREENBLATT, D. J., AND MARSHMAN, J. A. Interaction of disulfiram with benzodiazepines, 583  
 MADSEN, B. W. (See Selley et al.), 694  
 MAKKI, K. (See Perucca et al.), 46  
 MALAREK, D. (See Dixon et al.), 622  
 MARKS, B. H. (See Zarafonitis et al.), 127  
 MARONDE, R. F. (See Velasquez et al.), 186  
 MARSHALL, J. P. (See Kraus et al.), 411  
 MARSHMAN, J. A. (See MacLeod et al.), 583  
 MARTIN, P. R. (See MacLeod et al.), 583  
 MASON, D. T. (See Kudchodkar et al.), 354  
 MATERSON, B. J., OSTER, J. R., MICHAEL, U. F., BOLTON, S. M., BURTON, Z. C., STAUMBAUGH, J. E., AND MORLEDGE, J. Dose response to chlorthalidone in patients with mild hypertension, 192  
 MCINTYRE, B. A., PHILIP, R. B., AND INWOOD, M. J. Effect of ibuprofen on platelet function in normal subjects and hemophilic patients, 616  
 MCIVER, M. (See Back et al.), 438  
 MCLEAN, A. J., McNAMARA, P. J., DUSOUCHE, P., GIBALDI, M., AND LALKA, D. Food, splanchnic blood flow, and bioavailability of drugs subject to first-pass metabolism, 5 (Commentary)  
 MCMAHON, F. G. (See Jain et al.), 69  
 McNAMARA, P. (See Koupe et al.), 571  
 McNAMARA, P. J. (See Gibaldi et al.), 1 (Commentary)  
 —. (See McLean et al.), 5 (Commentary)  
 MEFFIN, P. J., WINKLE, R. A., PETERS, F. A., AND HARRISON, D. C., with the technical assistance of HARAPAT, S. R., AND YEE, Y.-G. Dose-dependent acebutolol disposition after oral administration, 542  
 MEISTER, S. G. (See Engel et al.), 274  
 MICHAEL, U. F. (See Materson et al.), 192  
 MILLER, K. (See Schneck et al.), 714  
 MOHACSI, E. (See Dixon et al.), 622  
 MOLTKE, E. (See Waldorff et al.), 162  
 MOORE, J. (See Dixon et al.), 622  
 MORETTI-OJEMANN, L. (See Wilensky et al.), 22  
 MORLEDGE, J. (See Materson et al.), 192  
 MROSZCZAK, E. (See Runkel et al.), 706  
 MUCKLOW, J. C., BENDING, M. R., KAHN, G. C., AND DOLLERY, C. T. Drug concentration in saliva, 563  
 MURRAY, W. J. (See Hull et al.), 644

## N

- NARANG, P. K., CROUTHAMEL, W. G., CARLINER, N. H., AND FISHER, M. L. Lidocaine and its active metabolites, 654  
 NEIMS, A. H. (See Parsons and Neims), 40

- NEU, H. C. (See Pancoast and Neu), 108  
NIELSEN, O. G. (See Waldorff et al.), 162  
NIES, A. S. (See Rane et al.), 199  
NIMMO, W. S. (See Clements et al.), 420  
NOYES, R., JR. (See Jochimsen et al.), 223

O

- OGILVIE, R. I., PIAFSKY, K. M., AND RUEDY, J.  
Antihypertensive responses to spironolac-  
tone in normal renin hypertension, 525  
ORLANDO, J. R., DANAHY, D. T., LURIE, M., AND  
ARONOW, W. S. Effect of trimazosin on  
hemodynamics in chronic heart failure, 531  
ORME, M. L'E. (See Baber et al.), 298  
— (See Back et al.), 439, 448  
OSTER, J. R. (See Materson et al.), 192

P

- PANCOAST, S. J., AND NEU, H. C. Kinetics of mez-  
locillin and carbenicillin, 108  
PANDEY, G. N., BAKER, J., CHANG, S., AND DAVIS,  
J. M. Prediction of in vivo red cell/plasma  
Li<sup>+</sup> ratios by in vitro methods, 343  
PARK, B. K. (See Back et al.), 439  
PARSONNET, M. (See Dixon et al.), 622  
PARSONS, W. D., AND NEIMS, A. H. Effect of smok-  
ing on caffeine clearance, 40  
PENTIKAINEN, P. (See Carruthers et al.), 168  
PERCHALSKI, R. J. (See Bruni et al.), 324  
PEREL, J. M. (See Redmond et al.), 213  
PERRIER, D. (See Gwilt and Perrier), 154  
PERUCCA, E., MAKKI, K., AND RICHENS, A. Is  
phenytoin metabolism dose-dependent by  
enzyme saturation or by feedback inhibi-  
tion? 46  
PETERS, F. A. (See Meffin et al.), 542  
PHILIP, R. B. (See McIntyre et al.), 616  
PIAFSKY, K. M. (See Ogilvie et al.), 525  
PIRAINO, A. J. (See DiGregorio et al.), 720  
POLEY, G. E., JR., SHIVELY, C. A., AND VESELL, E.  
S. Diurnal rhythms of aminopyrine me-  
tabolism: Failure of sleep deprivation to af-  
fect them, 726  
POPE, H. G., JR. (See Cole et al.), 243  
POTVIN, A. R. (See Henderson et al.), 146  
POWER, L. H. (See Zarafonitis et al.), 127  
PRESCOTT, L. F. (See Clements et al.), 420  
PRICHARD, B. N. C. (See Richards et al.), 264

R

- RAMSAY, L. E. (See Lindsay et al.), 650  
RANE, A., VILLENEUVE, J. P., STONE, W. J., NIES,  
A. S., WILKINSON, G. R., AND BRANCH,  
R. A. Plasma binding and disposition of  
furosemide in the nephrotic syndrome and  
in uremia, 199  
REDMOND, G. P., BELL, J. J., AND PEREL, J. M.  
Effect of human growth hormone on  
amobarbital metabolism in children, 213

- REID, J. L. (See Bateman et al.), 459  
REIDENBERG, M. (See Dietrich et al.), 474  
REIDENBERG, M. M. (See Drayer et al.), 31  
RESTIVO, K. M. (See Drayer et al.), 31  
RICHARD, W. (See Jain et al.), 69  
RICHARDS, D. A., PRICHARD, B. N. C., AND DOBBS,  
R. J. Adrenoceptor blockade of the circula-  
tory responses to intravenous isoprotere-  
nol, 264  
RICHENS, A. (See Perucca et al.), 46  
RICHTER, E. (See Breimer et al.), 208  
RILEY, P. A., JR. (See Zarafonitis et al.), 127  
ROSE, A. S. (See Henderson et al.), 146  
ROWE, P. H. (See Back et al.), 439, 448  
RUCH, E. (See DiGregorio et al.), 720  
RUEDY, J. (See Ogilvie et al.), 525  
RUNKEL, R., MROSZCZAK, E., CHAPLIN, M.,  
SEVELIUS, H., AND SEGRE, E. Naprox-  
en-probenecid interaction, 706  
RUSSELL, M. A. H. (See Sutton et al.), 395  
RYAN, J. R. (See Jain et al.), 69

S

- SALIH, S. Y. (See Branch et al.), 283  
SAUNDERS, R. H. (See Anavekar et al.), 629  
SCHENKER, S. (See Kraus et al.), 411  
SCHENTAG, J. J. (See Jusko et al.), 406  
SCHNECK, D. W., SPROUSE, J. S., MILLER, K.,  
VARY, J. E., DEWITT, F. O., AND HAYES,  
A. H., JR. Plasma levels of free and acid-  
labile hydralazine: Effects of multiple dos-  
ing and of procainamide, 714  
SCHWARTZ, A. (See Drayer et al.), 31  
SEGRE, E. (See Runkel et al.), 706  
SELLERS, E. M. (See MacLeod et al.), 583  
SELLEY, M. L., MADSEN, B. W., AND THOMAS, J.  
Protein binding of tolmetin, 694  
SEVELIUS, H. (See Runkel et al.), 706  
SHADER, R. I., GEORGOTAS, A., GREENBLATT, D.  
J., HARMATZ, J. S., AND ALLEN, M. D.  
Impaired absorption of desmethyldiazepam  
from clorazepate by magnesium aluminum  
hydroxide, 308  
— (See Greenblatt et al.), 600  
SHIVELY, C. A. (See Poley et al.), 726  
SHOULSON, I. (See Anavekar et al.), 629  
SIBEON, R. (See Baber et al.), 298  
SIDELL, F. R. (See Josselson and Sidell), 95  
SILVA, O. L. (See Wisneski et al.), 219  
SIRTORI, C. R., FRANCESCHINI, G., GALLI-KIENLE,  
M., CIGHETTI, G., GALLI, G., BONDIOLI,  
A., AND CONTI, F. Disposition of met-  
formin (N,N-dimethylbiguanide) in man,  
683  
SJÖQVIST, F. (See Boëthius and Sjöqvist), 255  
(Commentary)  
SLAFT, J. (See Sunshine et al.), 555  
SMITH, E. (See Back et al.), 439, 448  
SMITH, R. B. (See Yakatan et al.), 90



- SODHI, H. S. (*See* Kudchodkar et al.), 354  
SORENSEN, U. (*See* Waldorff et al.), 162  
SPOUSE, J. S. (*See* Schneck et al.), 714  
STAMBAUGH, J. E. (*See* Materson et al.), 192  
STANSKI, D. R., GREENBLATT, D. J., AND LOWENSTEIN, E. Kinetics of intravenous and intramuscular morphine, 52  
STEINNESS, E. (*See* Krakauer and Steinness), 454  
— (*See* Waldorff et al.), 162  
STONE, W. J. (*See* Rane et al.), 199  
STOTE, R. M. (*See* Dubb et al.), 76  
SUNSHINE, A., LASKA, E., AND SLAFTA, J. Oral nefopam and aspirin, 555  
SUTTON, S. R., FEYERABEND, C., COLE, P. V., AND RUSSELL, M. A. H. Adjustment of smokers to dilution of tobacco smoke by ventilated cigarette holders, 395
- T*
- TANG, B. K. (*See* Kalow et al.), 576  
THOMAS, J. (*See* Selley et al.), 694  
THOMPSON, J. H. A "bodi of pharmacologifts," 493 (Commentary)  
TOURTELLOTTE, W. W. (*See* Henderson et al.), 146  
TROUPIN, A. S. (*See* Wilensky et al.), 22
- U*
- UNGER, D. (*See* Jain et al.), 69
- V*
- VAN HERICK, R., AND ARONOW, W. S. Effects of oxprenolol and propranolol on systolic time intervals, 678  
VANE, F. (*See* Klutch et al.), 287  
VARY, J. E. (*See* Schneck et al.), 714  
VELASQUEZ, M. T., WAN, S. H., AND MARONDE, R. F. Bumetanide-induced rise in plasma renin activity, 186  
VERSTEEG, K. (*See* Jochimsen et al.), 223  
VESELL, E. S. (*See* Poley et al.), 726  
VILLARREAL, H. J. (*See* Bruni et al.), 324  
VILLENEUVE, J. P. (*See* Rane et al.), 199
- W*
- WALDORFF, S., ANDERSON, J. D., HEEBOLL-NIELSEN, N., NIELSEN, O. G., MOLTKE, E., SORENSEN, U., AND STEINNESS, E. Spironolactone-induced changes in digoxin kinetics, 162  
WALLE, T., CONRADI, E. C., WALLE, U. K., FAGAN, T. C., AND GAFFNEY, T. E. The predictable relationship between plasma levels and dose during chronic propranolol therapy, 668  
WALLE, U. K. (*See* Walle et al.), 668  
WAN, S. H. (*See* Velasquez et al.), 186  
WARDELL, W. M. The drug lag revisited: Comparison by therapeutic area of patterns of drugs marketed in the United States and Great Britain from 1972 through 1976, 499  
—, HASSAR, M., ANAVEKAR, S. N., AND LASAGNA, L. The rate of development of new drugs in the United States, 1963 through 1975, 133  
— (*See* Anavekar et al.), 629  
WEISDORF, D., KRAMER, J., GOLDBARG, A., AND KLAWANS, H. L. Physostigmine for cardiac and neurologic manifestations of phenothiazine poisoning, 663  
WELCH, R. M. (*See* Findlay et al.), 60  
WERBELOW, J. (*See* Zarafonitis et al.), 127  
WILDER, B. J. (*See* Bruni et al.), 324  
WILENSKY, A. J., LEVY, R. H., TROUPIN, A. S., MORETTI-OJEMANN, L., AND FRIEL, P. Clorazepate kinetics in treated epileptics, 22  
WILKINSON, G. R. (*See* Kraus et al.), 411  
— (*See* Rane et al.), 199  
WILLIAMS, B. O. (*See* Hull et al.), 644  
WILLIS, P. W., III. (*See* Zarafonitis et al.), 127  
WILLMORE, L. J. (*See* Bruni et al.), 324  
WINKLE, R. A. (*See* Meffin et al.), 542  
WISNESKI, L. A., CROOM, W. P., SILVA, O. L., AND BECKER, K. L. Salmon calcitonin in hypercalcemia, 219
- Y*
- YAKATAN, G. J., SMITH, R. B., LEFF, R. D., AND KAY, J. L. Pharmacokinetic considerations in exchange transfusion in neonates, 90  
YEE, Y.-G. (*See* Meffin et al.), 542  
YOUNG, D. S. (*See* Friedman et al.), 16  
YOUNG, R. (*See* Dixon et al.), 622  
YUE, K. T. N., AND DAVIS, J. W. Effect of oral aspirin on "ecto-ATPase" activity of washed human platelets, 240  
YURCHAK, A. M. (*See* Jusko et al.), 406
- Z*
- ZARAFONETIS, C. J. D., RILEY, P. A., JR., WILLIS, P. W., III, POWER, L. H., WERBELOW, J., FARHAT, L., BECKWITH, W., AND MARKS, B. H. Clinically significant adverse effects in a Phase I testing program, 127  
ZILLY, W. (*See* Breimer et al.), 208



## Subject index

### A

- Absorption, diazepam: effect of antacids and food (Greenblatt et al.), 600
- impaired, of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide (Shader et al.), 308
- Acebutolol disposition, dose-dependent, after oral administration (Meffin et al.), 542
- Acetaminophen absorption and gastric emptying in man, kinetics of (Clements et al.), 420
- phenacetin and, formation of thiomethyl metabolite of, in dogs and man (Klutch et al.), 287
- Acid, folic, effects of, on phenytoin kinetics in healthy subjects (Furlanut et al.), 294
- labile hydralazine, free and, plasma levels of; effects of multiple dosing and of procainamide (Schneck et al.), 714
- nicotinic, mechanisms of hypolipidemic action of (Kudchodkar et al.), 354
- valproic, steady-state kinetics of, in epileptic patients (Bruni et al.), 324
- ACTH in multiple sclerosis, methodology for analyzing clinical neurological data (Henderson et al.), 146 (Commentary)
- Adipose tissue, antilipolytic action on; mechanisms of hypolipidemic action of nicotinic acid (Kudchodkar et al.), 354
- Adrenoceptor blockade of circulatory responses to intravenous isoproterenol (Richards et al.), 264
- Aging and liver disease, effects of, on disposition of lorazepam (Kraus et al.), 411
- Alcohol, effects not antagonized by fenmetozole (Griffis et al.), 350
- Aldosterone, role of, in antihypertensive effect of spironolactone in essential hypertension (Benraad et al.), 638
- Aluminum hydroxide, magnesium, impaired absorption of desmethyldiazepam from clorazepate by (Shader et al.), 308
- Ambulatory patients, potential anticoagulant drug interactions in (Hull et al.), 644
- American Society for Clinical Pharmacology and Therapeutics, notes of, 126, 254
- statement of, on Drug Regulation Reform Act of 1978 (H.R. 11611), 374
- Aminopyrine metabolism, diurnal rhythms of; failure of sleep deprivation to affect them (Poley et al.), 726
- Amobarbital metabolism in children, effect of human growth hormone on (Redmond et al.), 213
- metabolites, distinctive patterns of (Kalow et al.), 576
- Analgesia, short half-life of morphine by intravenous and intramuscular injection indicating need for frequent dosage to maintain (Stanski et al.), 52
- Analgesic(s) actions, narcotic antagonist and, kinetics and RIA procedure for determination of HCMM, analogue of cyclorphan with (Dixon et al.), 622
- codeine-containing, plasma codeine and morphine concentrations after therapeutic oral doses of (Findlay et al.), 60
- effects, THC congener with, in animals, ineffective in doses used in pain due to cancer (Jochimsen et al.), 223
- Announcements, 382
- Antacids and food, effect of; diazepam absorption (Greenblatt et al.), 600
- Antipyrine metabolism in premenopausal women, effects of oral contraceptive on hepatic size and (Homeida et al.), 228
- in Sudan, study with; racial differences in drug metabolizing ability (Branch et al.), 283
- Apneic pre-term infants receiving theophylline, alterations in state in (Dietrich et al.), 474

July, pp. 1-126; August, pp. 127-254; September, pp. 255-382; October, pp. 383-492; November, pp. 493-628; December, pp. 629-750.

- Architecture, research, survey of, used for publications in general medical journals (Clinical biostatistics) (Feinstein), 117
- Artery, hepatic, infusions of thymidine, high-dose intravenous and (Ensminger and Frei), 610
- Arthropathy, hemophilic, advantages of ibuprofen over aspirin in treatment of (McIntyre et al.), 616
- Aspirin, advantages of ibuprofen over, in treatment of hemophilic arthropathy (McIntyre et al.), 616
- and aspirin-caffeine in postpartum pain relief (Jain et al.), 69
- oral, effect of, on "ecto-ATPase" activity of washed human platelets (Yue and Davis), 240
- nefopam and (Sunshine et al.), 555
- Asthma, long-term oral bronchodilator therapy of, with pirbuterol (Burki and Diamond), 84

*B*

- Benzodiazepines, effects of aging and liver disease on (Kraus et al.), 411
- interaction of disulfiram with (MacLeod et al.), 583
- Benzopyranoperidine,  $\Delta$ -9-THC congener, effect of, on pain (Jochimsen et al.), 223
- Beta adrenergic blockade in healthy men, short-term, serum and urine phosphate during (Lindsay et al.), 650
- adrenoceptor blocking drug, cardioselective, Phase I evaluation of pharmacodynamics of; pamtolol (Carruthers et al.), 168
- Biliary excretion of vincristine (Jackson et al.), 101
- Bioavailability of drugs subject to first-pass metabolism, food, splanchnic blood flow, and (McLean et al.), 5 (Commentary)
- low, part basis for low plasma concentrations of norethindrone in chronic use; kinetics of norethindrone in women (Back et al.), 448
- Biologic half-life of drugs, effect of plasma protein and tissue binding on (Gibaldi et al.), 1 (Commentary)
- Biostatistics, clinical. XLIV. A survey of the research architecture used for publications in general medical journals (Feinstein), 117
- XLV. The purposes and functions of criteria (Feinstein), 479
- Biotransformation, enhanced, of theophylline in marihuana and tobacco smokers (Jusko et al.), 406
- Bleeding time, smaller effects on, suggesting advantages of ibuprofen over aspirin in treatment of hemophilic arthropathy (McIntyre et al.), 616
- Blood concentration-time curve, area under, increased disproportionately with increasing oral doses of acebutolol (Meffin et al.), 542
- flow, splanchnic, food, and bioavailability of drugs subject to first-pass metabolism (McLean et al.), 5 (Commentary)
- "Bodi of pharmacologifts" (Thompson), 493 (Commentary)
- Books received, 628
- Brain, choroid plexus, and myocardium, digoxin concentration in, in old age (Krakauer and Steiness), 454
- Bronchodilator therapy, long-term oral, of asthma with pirbuterol (Burki and Diamond), 84
- Bumetanide-induced rise in plasma renin activity (Velasquez et al.), 186

*C*

- Caffeine, aspirin-, aspirin and, in postpartum pain relief (Jain et al.), 69
- clearance, effect of smoking on (Parsons and Neims), 40
- Calcitonin, salmon, in hypercalcemia (Wisneski et al.), 219
- Cancer, THC congener with analgesic effects in animals ineffective in doses used in pain due to (Jochimsen et al.), 223
- Carbamazepine and clonazepam, time-course of interaction between, in normal man (Lai et al.), 316
- Carbenicillin, kinetics of mezlocillin and (Pancoast and Neu), 108
- Cardiac and neurologic manifestations of phenothiazine poisoning, physostigmine for (Weisdorf et al.), 663
- patients with varying degrees of renal function, steady-state serum levels of quinidine and active metabolites in (Drayer et al.), 31
- Cardioselective beta adrenoceptor blocking drug, Phase I evaluation of pharmacodynamics of; pamtolol (Carruthers et al.), 168
- Cerebrospinal fluid production, evidence adduced suggesting that digoxin affects; digoxin concentration in choroid plexus, brain, and myocardium in old age (Krakauer and Steiness), 454
- Children, effect of human growth hormone on amobarbital metabolism in (Redmond et al.), 213
- Chloramphenicol, interaction of, with phenytoin and phenobarbital (Koup et al.), 571

- Chlordiazepoxide and diazepam metabolites, plasma clearance of decreased by disulfiram (MacLeod et al.), 583
- Chlorthalidone, dose response to, in patients with mild hypertension (Materson et al.), 192
- Choroid plexus, brain, and myocardium in old age, digoxin concentration in (Krakauer and Steiness), 454
- Cigarette holders, ventilated, adjustment of smokers to dilution of tobacco smoke by (Sutton et al.), 395
- Cimetidine, effect of, on renal function in normal man (Dubb et al.), 76
- Circulatory responses to intravenous isoproterenol, adrenoceptor blockade of (Richards et al.), 264
- Clinical biostatistics. XLIV. A survey of the research architecture used for publications in general medical journals (Feinstein) 117
- XLV. The purposes and functions of criteria (Feinstein), 479
- neurological data, methodology for analyzing: ACTH in multiple sclerosis (Henderson et al.), 146 (Commentary)
- Pharmacology and Therapeutics, American Society for, notes of, 126, 254
- thorny path of (Gross), 383 (Commentary)
- Clinically significant adverse effects in Phase I testing program (Zarafonitis et al.), 127 (Commentary)
- Clofibrate kinetics after single and multiple doses (Gugler and Hartlapp), 432
- Clonazepam, carbamazepine and, in normal man, time-course of interaction between (Lai et al.), 316
- Clonidine loading, oral, for rapid control of hypertension (Cohen and Katz), 11
- Clorazepate, impaired absorption of desmethyl-diazepam from, by magnesium aluminum hydroxide (Shader et al.), 308
- kinetics in treated epileptics (Wilensky et al.), 22
- Coagulant, anti-, drug interactions, potential, in ambulatory patients (Hull et al.), 644
- Codeine, plasma, and morphine concentrations after therapeutic oral doses of codeine-containing analgesics (Findlay et al.), 60
- Congestive heart failure, resistant, hemodynamic effects of dopamine in patients with (Durairaj and Haywood), 175
- Contraceptive, oral, effects of, on hepatic size and antipyrine metabolism in premenopausal women (Homeida et al.), 228
- Contractions, uterine, influence of; transplacental passage of diazepam during labor (Haram et al.), 590
- Correspondence, 253
- Corticosteroid, influence of, on hexobarbital and tolbutamide disposition (Breimer et al.), 208
- Criteria, purposes and functions of (Feinstein), 479 (Clinical biostatistics)
- Cyclorphan, kinetics and RIA procedure for determination of HCMM, analogue of (Dixon et al.), 622
- D*
- Depressant action, initial, furosemide effect intensified by probenecid after (Brater), 548
- Desmethyldiazepam, impaired absorption of, from clorazepate by magnesium aluminum hydroxide (Shader et al.), 308
- Diazepam absorption; effect of antacids and food (Greenblatt et al.), 600
- concentrations in parotid saliva, mixed saliva, and plasma (DiGregorio et al.), 720
- metabolites, chlordiazepoxide and, plasma clearance of decreased by disulfiram (MacLeod et al.), 583
- transplacental passage of, during labor; influence of uterine contractions (Haram et al.), 590
- Digitoxicity, concurrent use of spironolactone and digoxin in relation to (Waldorff et al.), 162
- Digoxin concentration in choroid plexus, brain, and myocardium in old age (Krakauer and Steiness), 454
- kinetics, spironolactone-induced changes in (Waldorff et al.), 162
- Disease, liver, aging and, effects of, on disposition of lorazepam (Kraus et al.), 411
- Parkinson's, metoclopramide in (Bateman et al.), 459
- Disulfiram, interaction of, with benzodiazepines (MacLeod et al.), 583
- Diurnal rhythms of aminopyrine metabolism: failure of sleep deprivation to affect them (Poley et al.), 726
- Dobutamine pharmacokinetics in severe heart failure (Kates and Leier), 537
- Dogs and man, formation of thiomethyl metabolite of phenacetin and acetaminophen in (Klutch et al.), 287
- Dopamine blocker apparently safely used for nausea in patients with Parkinson's disease (Bateman et al.), 459
- hemodynamic effects of, in patients with resistant congestive heart failure (Durairaj and Haywood), 175

Dosage calculation, safe, in use of flucytosine in normal patients and in those with severe renal impairment (Cutler et al.), 333

intervals of drugs, doses and—clinical practice and pharmacokinetic principles (Boëthius and Sjöqvist), 255 (Commentary)

Dose-dependent acebutolol disposition after oral administration (Meffin et al.), 542

Dose(s) and dosage intervals of drugs—clinical practice and pharmacokinetic principles (Boëthius and Sjöqvist), 255 (Commentary)

plasma levels and, predictable relationship between, during chronic propranolol therapy (Walle et al.), 668

response to chlorthalidone in patients with mild hypertension (Materson et al.), 192

single and multiple, clofibrate kinetics after (Gugler and Hartlapp), 432

Dosing, multiple, radioimmunoassay and concentrations during; kinetics of norethindrone in women (Back et al.), 439

Doxycycline kinetics, minocycline and, in chronic renal failure (Heaney and Eknoyan), 233

Drug(s) abuse due to central stimulant action, study using new approach to testing of new drugs with possible potential for (Cole et al.), 243

biologic half-life of, effect of plasma protein and tissue binding on (Gibaldi et al.), 1 (Commentary)

cardioselective beta adrenoceptor blocking, Phase I evaluation of pharmacodynamics of; pamtolol (Carruthers et al.), 168

concentration in saliva (Mucklow et al.), 563

development, survey which provides baseline against which trends in can be measured (Wardell et al.), 133 (Commentary)

doses and dosage intervals of—clinical practice and pharmacokinetic principles (Boëthius and Sjöqvist), 255 (Commentary)

interactions, potential anticoagulant, in ambulatory patients (Hull et al.), 644

lag revisited; comparison by therapeutic area of patterns of drugs marketed in United States and Great Britain from 1972 through 1976 (Wardell), 499

metabolizing ability, racial differences in: study with antipyrine in Sudan (Branch et al.), 283

new, with possible potential for drug abuse due to central stimulant action, new approach to testing of (Cole et al.), 243

## Drugs, new—Cont'd

in United States, rate of development of, 1963 through 1975 (Wardell et al.), 133 (Commentary)

plasma protein binding and distribution characteristics of, as indices of their hemodialyzability (Gwilt and Perrier), 154 (Commentary)

Regulation Reform Act of 1978 (H.R. 11611), statement of American Society for Clinical Pharmacology and Therapeutics on, 374

-test interactions, automated monitoring of (Friedman et al.), 16

## E

Enzymatic metabolism of clonazepam induced by carbamazepine (Lai et al.), 316

Enzyme saturation or feedback inhibition, phenytoin metabolism dose-dependent by (Perucca et al.), 46

Epileptic(s) patients, steady-state kinetics of valproic acid in (Bruni et al.), 324

treated, clonazepam kinetics in (Wilensky et al.), 22

Ethanol, fenmetozole and, combined effects of (Griffis et al.), 350

## F

Feedback inhibition, enzyme saturation or, phenytoin metabolism dose-dependent by? (Perucca et al.), 46

Fenmetozole and ethanol, combined effects of (Griffis et al.), 350

Fistula, biliary, case with, in biliary excretion of vincristine (Jackson et al.), 101

Flucytosine kinetics in subjects with normal and impaired renal function (Cutler et al.), 333

Folic acid, effects of, on phenytoin kinetics in healthy subjects (Furlanut et al.), 294

Food, antacids and, effect of; diazepam absorption (Greenblatt et al.), 600

splanchnic blood flow, and bioavailability of drugs subject to first-pass metabolism (McLean et al.), 5 (Commentary)

Furosemide, placental transfer of (Beermann et al.), 560

plasma binding and disposition of, in nephrotic syndrome and in uremia (Rane et al.), 199

response, effects of probenecid on (Brater), 548

## G

Gastric emptying in man, kinetics of acetaminophen absorption and (Clements et al.), 420

Great Britain, United States and, comparison by therapeutic area of patterns of drugs marketed in, from 1972 through 1976 (Wardell), 499

- Growth hormone, human, effect of, on amobarbital metabolism in children (Redmond et al.), 213
- Gynecomastia induced in normal males by spironolactone (Huffman et al.), 465

## H

- Heart failure, chronic, effect of trimazosin on hemodynamics in (Orlando et al.), 531
- resistant congestive, hemodynamic effects of dopamine in patients with (Durairaj and Haywood), 175
- severe, dobutamine pharmacokinetics in (Kates and Leier), 537
- Hemodialyzability, plasma protein binding and distribution characteristics of drugs as indices of (Gwilt and Perrier), 154
- Hemodynamic(s) in chronic heart failure, effect of trimazosin on (Orlando et al.), 531
- effects of dopamine in patients with resistant congestive heart failure (Durairaj and Haywood), 175
- Hemophiliac patients, effect of ibuprofen on platelet function in normal subjects and (McIntyre et al.), 616
- Hepatic artery infusions of thymidine, high-dose intravenous and (Ensminger and Frei), 610
- metabolism of tolbutamide and hexobarbital, no significant effect on, observed after 10 days of prednisone treatment (Breimer et al.), 208
- size, effects of oral contraceptive on, and antipyrine metabolism in premenopausal women (Homeida et al.), 228
- Hexobarbital and tolbutamide disposition, influence of corticosteroid on (Breimer et al.), 208
- Hormone, human growth, effect of, on amobarbital metabolism in children (Redmond et al.), 213
- Human platelets, washed, effect of oral aspirin on "ecto-ATPase" activity of (Yue and Davis), 240
- Hydralazine, free and acid-labile, plasma levels of: effects of multiple dosing and of procainamide (Schneck et al.), 714
- Hydroxide, magnesium aluminum, impaired absorption of desmethyldiazepam from clorazepate by (Shader et al.), 308
- (-)-2-Hydroxy-N-cyclopropylmethylmorphinan; radioimmunoassay and pharmacokinetic profile (Dixon et al.), 622
- Hypercalcemia, salmon calcitonin in (Wisneski et al.), 219
- Hypertension, essential, role of aldosterone in antihypertensive effect of spironolactone in (Benraad et al.), 638

## Hypertension—Cont'd

- mild, dose response to chlorthalidone in patients with (Materson et al.), 192
- normal renin, antihypertensive responses to spironolactone in (Ogilvie et al.), 525
- oral clonidine loading for rapid control of (Cohen and Katz), 11
- Hypolipidemic action of nicotinic acid, mechanisms of (Kudchodkar et al.), 354

## I

- Ibuprofen, effect of, on platelet function in normal subjects and hemophiliac patients (McIntyre et al.), 616
- Indomethacin and probenecid, interaction between (Baber et al.), 298
- Infants, apneic state in pre-term receiving theophylline, alterations in (Dietrich et al.), 474
- Infusions, high-dose intravenous and hepatic artery, of thymidine (Ensminger and Frei), 610
- Injections, intravenous, reduced transfer during contractions suggesting timing (Haram et al.), 590
- Intravenous and hepatic artery infusions of thymidine, high-dose (Ensminger and Frei), 610
- Ionized drugs not providing reproducible correlations between saliva and plasma (Mucklow et al.), 563
- Isoproterenol, intravenous, adrenoceptor blockade of circulatory responses to (Richards et al.), 264

## K

- Kidney, metformin actively and rapidly secreted by (Sirtori et al.), 683
- Kinetic(s) of acetaminophen absorption and gastric emptying in man (Clements et al.), 420
- clofibrate, after single and multiple doses (Gugler and Hartlapp), 432
- clorazepate, in treated epileptics (Wilensky et al.), 22
- digoxin, spironolactone-induced changes in (Waldorff et al.), 162
- flucytosine, in subjects with normal and impaired renal function (Cutler et al.), 333
- of intravenous and intramuscular morphine (Stanski et al.), 52
- of mezlocillin and carbenicillin (Pancoast and Neu), 108
- of norethindrone in women; radioimmunoassay and concentrations during multiple dosing (Back et al.), 439
- single-dose kinetics (Back et al.), 448
- phenytoin, in healthy subjects, effects of folic acid on (Furlanut et al.), 294

## Kinetics—Cont'd

- pralidoxime, effect of intravenous thiamine on (Josselson and Sidell), 95
- steady-state, of valproic acid in epileptic patients (Bruni et al.), 324

## L

- Labetalol and propranolol, differences between (Richards et al.), 264
- Labor, transplacental passage of diazepam during; influence of uterine contractions (Haram et al.), 590
- Li<sup>+</sup> ratios, in vivo red cell/plasma, prediction of, by in vitro methods (Pandey et al.), 343
- Lidocaine and its active metabolites (Narang et al.), 654
- Liver disease, aging and, effects of, on disposition of lorazepam (Kraus et al.), 411
- Lorazepam, effects of aging and liver disease on disposition of (Kraus et al.), 411

## M

- Magnesium aluminum hydroxide, impaired absorption of desmethyldiazepam from clorazepate by (Shader et al.), 308
- Males, normal, gynecomastia induced in, by spironolactone (Huffman et al.), 465
- Man, disposition of metformin (N,N-dimethylbiguanide) in (Sirtori et al.), 683
  - dogs and, formation of thiomethyl metabolite of phenacetin and acetaminophen in (Klutch et al.), 287
  - kinetics of acetaminophen absorption and gastric emptying in (Clements et al.), 420
  - normal, carbamazepine and clonazepam in, time-course of interaction between (Lai et al.), 316
  - effect of cimetidine on renal function in (Dubb et al.), 76
- Marihuana and tobacco smokers, enhanced biotransformation of theophylline in (Jusko et al.), 406
- Maternal plasma concentrations approached; placental transfer of furosemide (Beer-mann et al.), 560
- Men, healthy, serum and urine phosphate during short-term  $\beta$ -adrenergic blockade in (Lindsay et al.), 650
- Menopausal, pre-, women, effects of oral contraceptive on hepatic size and antipyrine metabolism in (Homeida et al.), 228
- Metabolism, aminopyrine, diurnal rhythms of: failure of sleep deprivation to affect them (Poley et al.), 726
  - amobarbital, in children, effect of human growth hormone on (Redmond et al.), 213
  - antipyrine, effects of oral contraceptive on hepatic size and, in premenopausal women (Homeida et al.), 228

## Metabolism—Cont'd

- first-pass, food, splanchnic blood flow, and bioavailability of drugs subject to (McLean et al.), 5 (Commentary)
- phenytoin, dose-dependent by enzyme saturation or by feedback inhibition? (Perucca et al.), 46
- Metabolite(s), active, lidocaine and (Narang et al.), 654
  - steady-state serum levels of quinidine and, in cardiac patients with varying degrees of renal function (Druyer et al.), 31
- amobarbital, distinctive patterns of (Kalow et al.), 576
- thiomethyl, of phenacetin and acetaminophen in dogs and man, formation of (Klutch et al.), 287
- Metabolizing ability, drug, racial differences in: study with antipyrine in Sudan (Branch et al.), 283
- Metformin (N,N-dimethylbiguanide), disposition of, in man (Sirtori et al.), 683
- Metoclopramide in Parkinson's disease (Bateman et al.), 459
- Minocycline and doxycycline kinetics in chronic renal failure (Heaney and Eknayan), 233
- Monitoring, automated, of drug-test interactions (Friedman et al.), 16
- Morphine concentrations, plasma codeine and, after therapeutic oral doses of codeine-containing analgesics (Findlay et al.), 60
  - intravenous and intramuscular, kinetics of (Stanski et al.), 52
- Multiple sclerosis, ACTH in; methodology for analyzing clinical neurological data (Henderson et al.), 146
- Myocardium, choroid plexus, brain, and, in old age, digoxin concentration in (Krakauer and Steiness), 454

## N

- Naproxen-probenecid interaction (Runkel et al.), 706
- Narcotic antagonist and analgesic actions, kinetics and RIA procedure for determination of HCMM, analogue of cyclorphan with (Dixon et al.), 622
- Nausea, dopamine blocker apparently safely used for, in patients with Parkinson's disease (Bateman et al.), 459
- Nefopam, oral, and aspirin (Sunshine et al.), 555
- Neonates, pharmacokinetic considerations in exchange transfusion in (Yakatan et al.), 90
- Nephrotic syndrome and uremia, plasma binding and disposition of furosemide in (Rane et al.), 199



- Neurologic(al), cardiac and, manifestations of phenothiazine poisoning, physostigmine for (Weisdorf et al.), 663
- data, clinical, methodology for analyzing: ACTH in multiple sclerosis (Henderson et al.), (Commentary)
- Nicotine, smokers compensate for tendency of ventilated cigarette holders to lower availability of (Sutton et al.), 395
- Nicotinic acid, mechanisms of hypolipidemic action of (Kudchodkar et al.), 354
- Norethindrone, kinetics of, in women; radioimmunoassay and concentrations during multiple dosing (Back et al.), 439
- in women, kinetics of; single-dose kinetics (Back et al.), 448

# O

- Oral administration, dose-dependent acebutolol disposition after (Meffin et al.), 542
- bronchodilator therapy, long-term, of asthma with pirbuterol (Burki and Diamond), 84
- nefopam and aspirin (Sunshine et al.), 555
- Oxprenolol and propranolol, effects of, on systolic time intervals (van Herick and Aronow), 678

# P

- Pain, effect of benzopyranoperidine,  $\Delta$ -9-THC congener, (Jochimsen et al.), 223
- relief, postpartum, aspirin and aspirin-caffeine in (Jain et al.), 69
- Pamatolol: Phase I evaluation of pharmacodynamics of cardioselective beta adrenoceptor blocking drug (Carruthers et al.), 168
- Parkinson's disease, metoclopramide in (Bateman et al.), 459
- Parotid saliva, mixed saliva, and plasma, diazepam concentrations in (DiGregorio et al.), 720
- and whole saliva in prediction of serum total and free phenytoin concentrations (Anavekar et al.), 629
- Pharmacodynamics of cardioselective beta adrenoceptor blocking drug, Phase I evaluation of; pamatolol (Carruthers et al.), 168
- Pharmacokinetic(s) considerations in exchange transfusion in neonates (Yakatan et al.), 90
- dobutamine, in severe heart failure (Kates and Leier), 537
- principles, clinical practice and—doses and dosage intervals of drugs (Boëthius and Sjöqvist), 255 (Commentary)
- profile, radioimmunoassay and; (-)-2-hydroxy-N-cyclopropylmethylmorphinan (Dixon et al.), 622
- "Pharmacologifts, bodi of" (Thompson), 493 (Commentary)

- Pharmacology, Clinical, and Therapeutics, notes of American Society for, 126, 254
- thorny path of (Gross), 383 (Commentary)
- statement of, on Drug Regulation Reform Act of 1978 (H.R. 11611), 374
- Phase I testing program, clinically significant, adverse effects in (Zarafonitis et al.), 127 (Commentary)
- Phenacetin and acetaminophen, formation of thiomethyl metabolite of, in dogs and man (Klutch et al.), 287
- Phenformin, metformin relatively less toxic than (Sirtori et al.), 683
- Phenobarbital, phenytoin and, interaction of chloramphenicol with (Koup et al.), 571
- Phenothiazine poisoning, physostigmine for cardiac and neurologic manifestations of (Weisdorf et al.), 663
- Phenytoin concentrations, serum total and free, parotid and whole saliva in prediction of (Anavekar et al.), 629
- kinetics in healthy subjects, effects of folic acid on (Furlanut et al.), 294
- metabolism, dose-dependent by enzyme saturation or by feedback inhibition? (Perucca et al.), 46
- and phenobarbital, interaction of chloramphenicol with (Koup et al.), 571
- therapy, 253 (Correspondence)
- Phosphate, serum and urine, during short-term  $\beta$ -adrenergic blockade in healthy men (Lindsay et al.), 650
- Physostigmine for cardiac and neurologic manifestations of phenothiazine poisoning (Weisdorf et al.), 663
- Pirbuterol, long-term oral bronchodilator therapy of asthma with (Burki and Diamond), 84
- Placental transfer of furosemide (Beermann et al.), 560
- Plasma binding and disposition of furosemide in nephrotic syndrome and in uremia (Rane et al.), 199
- codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics (Findlay et al.), 60
- concentration of norethindrone in chronic use, low bioavailability part basis for; kinetics of norethindrone in women (Back et al.), 448
- level(s) and dose, predictable relationship between, during chronic propranolol therapy (Walle et al.), 668
- of free and acid-labile hydralazine: effects of multiple dosing and of procainamide (Schneck et al.), 714
- increased by trebling oral dose of norethindrone acetate; kinetics of norethindrone in women (Back et al.), 439



## Plasma—Cont'd

- nonionized drugs provide reproducible correlations between saliva and (Mucklow et al.), 563
- parotid saliva, mixed saliva, and, diazepam concentrations in (DiGregorio et al.), 720
- protein binding and distribution characteristics of drugs as indices of their hemodialyzability (Gwilt and Perrier), 154 (Commentary)
- progressive falls with rise in plasma concentrations; clofibrate kinetics after single and multiple doses (Gugler and Hartlapp), 432
- and tissue binding, effect of, on biologic half-life of drugs (Gibaldi et al.), 1 (Commentary)
- /red cell  $\text{Li}^+$  ratios, in vivo, prediction of, by in vitro methods (Pandey et al.), 343
- renin activity, bumetanide-induced rise in (Velasquez et al.), 186
- umbilical cord, placental transfer of furosemide indicated by its presence in (Beer-mann et al.), 560
- Platelets, function, effect of ibuprofen on, in normal subjects and hemophiliac patients (McIntyre et al.), 616
- washed human, effect of oral aspirin on "ecto-ATPase" activity of (Yue and Davis), 240
- Poisoning, phenothiazine, physostigmine for cardiac and neurologic manifestations of (Weisdorf et al.), 663
- Postpartum pain relief, aspirin and aspirin-caffeine in (Jain et al.), 69
- Pralidoxime kinetics, effect of intravenous thiamine on (Josselson and Sidell), 95
- Prednisone treatment, no significant effect on hepatic metabolism of tolbutamide and hexobarbital observed after 10 days of (Breimer et al.), 208
- Premature infants, theophylline decreased apneic episodes in; alterations in state in apneic pre-term infants receiving theophylline (Dietrich et al.), 474
- Probenecid, effects of, on furosemide response (Brater), 548
- indomethacin and, interaction between (Baber et al.), 298
- naproxen-, interaction (Runkel et al.), 706
- Procainamide, effect(s) of, on induced ventricular tachycardia (Engel et al.), 274
- of multiple dosing and of; plasma levels of free and acid-labile hydralazine (Schneck et al.), 714
- Propranolol and labetalol, differences between (Richards et al.), 264
- oxprenolol and, effects of, on systolic time intervals (van Herick and Aronow), 678

## Propranolol—Cont'd

- therapy, chronic, predictable relationship between plasma levels and dose during (Walle et al.), 668
- Protein binding, plasma, and distribution characteristics of drugs as indices of their hemodialyzability (Gwilt and Perrier), 154 (Commentary)
- of tolmetin (Selley et al.), 694

## Q

- Quinidine and active metabolites in cardiac patients with varying degrees of renal function, steady-state serum levels of (Drayer et al.), 31

## R

- Racial differences in drug metabolizing ability: study with antipyrine in Sudan (Branch et al.), 283
- Radioimmunoassay and concentrations during multiple dosing; kinetics of norethindrone in women (Back et al.), 439
- and pharmacokinetic profile; (-)-2-hydroxy-N-cyclopropylmethylmorphinan (Dixon et al.), 622
- Red cell/plasma  $\text{Li}^+$  ratios, in vivo, prediction of, by in vitro methods (Pandey et al.), 343
- Renal clearance of naproxen depressed by probenecid (Runkel et al.), 706
- failure, chronic, minocycline and doxycycline kinetics in (Heaney and Eknayan), 233
- function, normal and impaired, flucytosine kinetics in subjects with (Cutler et al.), 333
- in normal man, effect of cimetidine on (Dubb et al.), 76
- steady-state serum levels of quinidine and active metabolites in cardiac patients with varying degrees of (Drayer et al.), 31
- Renin activity, plasma, bumetanide-induced rise in (Velasquez et al.), 186
- hypertension, normal, antihypertensive responses to spironolactone in (Ogilvie et al.), 525
- Research architecture used for publications in general medical journals, survey of (Feinstein), 117 (Clinical biostatistics)

## S

- Saliva, drug concentration in (Mucklow et al.), 563
- parotid, mixed, and plasma, diazepam concentrations in (DiGregorio et al.), 720
- and whole, in prediction of serum total and free phenytoin concentrations (Anavekar et al.), 629
- Salmon calcitonin in hypercalcemia (Wisneski et al.), 219
- Sclerosis, multiple, ACTH in; methodology for analyzing clinical neurological data in (Henderson et al.), 146 (Commentary)

Serum levels, steady-state, of quinidine and active metabolites in cardiac patients with varying degrees of renal function (Drayer et al.), 31

total and free phenytoin concentrations, parotid and whole saliva in prediction of (Anavekar et al.), 629

and urine phosphate during short-term  $\beta$ -adrenergic blockade in healthy men (Lindsay et al.), 650

Sleep deprivation, failure of, to affect diurnal rhythms of aminopyrine metabolism (Poley et al.), 726

Smokers, adjustment of, to dilution of tobacco smoke by ventilated cigarette holders (Sutton et al.), 395

marihuana and tobacco, enhanced biotransformation of theophylline in (Jusko et al.), 406

Smoking, effect of, on caffeine clearance (Parsons and Neims), 40

Spironolactone, antihypertensive responses to, in normal renin hypertension (Ogilvie et al.), 525

gynecomastia induced in normal males by (Huffman et al.), 465

-induced changes in digoxin kinetics (Waldorff et al.), 162

role of aldosterone in antihypertensive effect of, in essential hypertension (Benraad et al.), 638

Splanchnic blood flow, food, and bioavailability of drugs subject to first-pass metabolism (McLean et al.), 5 (Commentary)

Stimulants, assessing subjective effects of, in casual users (Cole et al.), 243

Sudan, study with antipyrine in; racial differences in drug metabolizing ability (Branch et al.), 283

Systolic time intervals, effects of oxprenolol and propranolol on (van Herick and Aronow), 678

T

Tachycardia, induced ventricular, effect of procainamide on (Engel et al.), 274

Testing program, clinically significant Phase I, adverse effects in (Zarafonitis et al.), 127 (Commentary)

THC congener,  $\Delta$ -9-, benzopyranoperidine, effect of, on pain (Jochimsen et al.), 223

Theophylline, alterations in state in apneic pre-term infants receiving (Dietrich et al.), 474

enhanced biotransformation of, in marihuana and tobacco smokers (Jusko et al.), 406

Therapeutic(s), American Society for Clinical Pharmacology and, notes of, 126, 254

Therapeutic(s)—Cont'd

area, comparison by, of patterns of drugs marketed in United States and Great Britain from 1972 through 1976 (Wardell), 499

statement of American Society for Clinical Pharmacology and, on Drug Regulation Reform Act of 1978 (H.R. 11611), 374

Therapy, chronic propranolol, predictable relationship between plasma levels and dose during (Walle et al.), 668

$Li^+$ , predetermining patient response to (Pandey et al.), 343

Thiamine, intravenous, effect of, on pralidoxime kinetics (Josselson and Sidell), 95

Thiomethyl metabolite of phenacetin and acetaminophen in dogs and man, formation of (Klutch et al.), 287

Thorny path of clinical pharmacology (Gross), 383 (Commentary)

Thymidine, high-dose intravenous and hepatic artery infusions of (Ensminger and Frei), 610

Tissue binding, effect of plasma protein and, on biologic half-life of drugs (Gibaldi et al.), 1 (Commentary)

Tobacco smoke, adjustment of smokers to dilution of, by ventilated cigarette holders (Sutton et al.), 395

smokers, marihuana and, enhanced biotransformation of theophylline in (Jusko et al.), 406

Tolbutamide disposition, hexobarbital and, influence of corticosteroid on (Breimer et al.), 208

Tolmetin, protein binding of (Selley et al.), 694

Transfusion, exchange, in neonates, pharmacokinetic considerations in (Yakatan et al.), 90

Trimazosin, effect of, on hemodynamics in chronic heart failure (Orlando et al.), 531

U

Umbilical cord plasma, placental transfer of furosemide indicated by its presence in (Beermann et al.), 560

United States and Great Britain, comparison by therapeutic area of patterns of drugs marketed in, from 1972 through 1976 (Wardell), 499

rate of development of new drugs in, 1963 through 1975 (Wardell et al.), 133 (Commentary)

Uremia, plasma binding and disposition of furosemide in nephrotic syndrome and in (Rane et al.), 199

Urine, naproxen conjugates reduced in by probenecid (Runkel et al.), 706

## Urine—Cont'd

phosphate, serum and, during short-term  $\beta$ -adrenergic blockade in healthy men (Lindsay et al.), 650

Uterine contractions, influence of; transplacental passage of diazepam during labor (Haram et al.), 590

## V

Valproic acid, steady-state kinetics of, in epileptic patients (Bruni et al.), 324

Vasodilator, trimazosin relatively long-acting; effect of on hemodynamics in chronic heart failure (Orlando et al.), 531

Ventricular failure, left, trimazosin relatively long-acting vasodilator appearing to be effective in patients with (Orlando et al.), 531

tachycardia, induced, effect of procainamide on (Engel et al.), 274

Vincristine, biliary excretion of (Jackson et al.), 101

## W

Women, kinetics of norethindrone in; radioimmunoassay and concentrations during multiple dosing (Back et al.), 439  
single-dose kinetics (Back et al.), 448

